Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Mebio Biotechnology Co. Ltd. currently manages 1 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is situated in 1 distinct art units, indicating a localized prosecution effort. The 1 pending office actions represent the total current volume for the company in this sector.
The portfolio is assigned to 1 distinct examiners, meaning there is no diversity in examiner perspectives across the current filings. DIBRINO, MARIANNE is the busiest examiner, currently overseeing 1 busiest examiner pending actions. This 1 busiest examiner pending actions constitutes the entire pending portfolio.
Because the 1 distinct examiners is the only individual reviewing the company's work, the prosecution strategy is dependent on the interactions with DIBRINO, MARIANNE. The 1 distinct art units involved further limits the variety of procedural environments the company faces. This concentration simplifies the management of the matters but increases the impact of an individual examiner's discretion.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIBRINO, MARIANNE | 1 | 42.8% | +42.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19317201 | Nanobody targeting IL-23A and application thereof | DIBRINO, MARIANNE | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19317201 | Nanobody targeting IL-23A and application thereof | DIBRINO, MARIANNE | 1641 | §112 | Non-Final OA | — | Pending | Sep 03, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Mebio Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Marianne Dibrino has the most, with 1 of Beijing Mebio Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
